1. Faculty of Advanced Medical Science Technology, Golestan University of Medical Sciences, Gorgan, Iran ; 2. Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, Iran ; 3. Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Cell J. 2012 Summer;14(2):76-81. Epub 2012 Aug 31.
Lentivirus-derived vectors are among the most promising viral vectors for gene therapy which is currently available, but their use in clinical practice is limited due to associated risk of insertional mutagenesis. Gene targeting is an ideal method for gene therapy, but it has low efficiency in comparison to viral vector methods. In this study, we are going to design and construct an integrase-minus lentiviral vector. This vector is suitable for transient expression of gene and gene targeting with viral vector.
In this experimental study, three missense mutations were induced in the catalytic domain of Integrase gene in the pLP1 plasmid and resulted D64V, D116A and E152G changes in the amino acid sequence through site directed mutagenesis. The pLenti6.2-GW/EmGFP transfer vector, associated with native and mutated packaging mix, was transfected into 293T cell line. In order to titer the lentivirus stock, the viruses were harvested. Finally, the viruses transduced into COS-7 cell line to assess green fluorescent protein (GFP) gene expression by a fluorescence microscopy.
Recombinant and wild lentiviruses titer was about 5~8×10(6) transducing units/ml in COS-7 cell line. The number of GFP-positive cells transduced with native viruses was decreased slightly during two weeks after viral transduction. In contrast, in the case of integrase-minus viruses, a dramatic decrease in the number of GFP positive cells was observed.
This study was conducted to overcome the integration of lentiviral genome into a host genome. Nonintegrating lentiviral vectors can be used for transient gene expression and gene targeting if a Target gene cassette is placed in the lentivirus gene structure. This combination method decreases disadvantages of both processes, such as random integration of lentiviruses and low efficiency of gene targeting.
慢病毒衍生载体是目前可用的基因治疗中最有前途的病毒载体之一,但由于插入突变的相关风险,其在临床实践中的应用受到限制。基因打靶是基因治疗的理想方法,但与病毒载体方法相比,其效率较低。在这项研究中,我们将设计并构建一种整合酶缺失的慢病毒载体。该载体适合于基因的瞬时表达和基因靶向的病毒载体。
在这项实验研究中,通过定点突变在 pLP1 质粒的整合酶基因的催化结构域中诱导了三个错义突变,导致氨基酸序列中的 D64V、D116A 和 E152G 改变。将 pLenti6.2-GW/EmGFP 转移载体与天然和突变的包装混合物一起转染 293T 细胞系。为了滴定慢病毒 stock,收获病毒。最后,将病毒转导到 COS-7 细胞系中,通过荧光显微镜评估绿色荧光蛋白(GFP)基因的表达。
重组和野生慢病毒滴度在 COS-7 细胞系中约为 5~8×10(6)个转导单位/ml。在用天然病毒转导后两周内,GFP 阳性细胞的数量略有减少。相比之下,在整合酶缺失病毒的情况下,GFP 阳性细胞的数量急剧减少。
本研究旨在克服慢病毒基因组整合到宿主基因组中。如果靶基因盒置于慢病毒基因结构中,非整合慢病毒载体可用于瞬时基因表达和基因靶向。这种组合方法降低了两种过程的缺点,如慢病毒的随机整合和基因靶向的低效率。